Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...
Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...
The drug has given promising results for the treatment of multiple myeloma, a rare form of blood cancer. The market for such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback